Nutlin-3a

Catalog No.S8059 Synonyms: (-)-Nutlin-3

Nutlin-3a Chemical Structure

Molecular Weight(MW): 581.49

Nutlin-3a, the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay.

Size Price Stock Quantity  
USD 197 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 11 Publications

7 Customer Reviews

  • Nutlin-3a preserved p53 expression without influencing high glucose (HG)-induced podocyte impairment. A-D: cultured podocytes were pre-treated by nutlin-3a for 2 hrs before subjected to HG treatment. Western blotting gel documents (A) and summarized data (B) showing the expression of p53 and MDM2 in podocytes under HG exposure for 24 hrs. n = 4. Western blotting gel documents (C) and summarized data (D) showing the expression of Desmin in podocytes under HG exposure for 24 hrs. n = 3. *P < 0.05 vs. Ctrl, #P < 0.05 vs. Vehl + HG. Ctrl: control; Vehl: vehicle; nutlin-3a: nutlin-3a treatment.

    J Cell Mol Med, 2017, 21(12):3435-3444. Nutlin-3a purchased from Selleck.

    Twenty-four hours after plating 1×105 Shh-EGFP cells, media was changed to serum-free media containing vehicle, 8µM Nutlin-3a, and/or Shh (3µg/mL). Cells were also transduced with lentivirus containing pLKO.1 empty vector or LentiORF-YFP-WIP1. 48 hours later, cells were fixed in 4% paraformaldehyde, permeabilized, incubated with α-WIP1 or α-Ki-67 antibody, and mounted using media containing DAPI. Scale bar, 100µm.

    Oncogene, 2016, 35(42):5552-5564. Nutlin-3a purchased from Selleck.

  • (a) Westernblot analysis of the whole cell lysate from WT-MTEC, KO-MTEC and 1601 treated with or without Nutlin-3a (15 μM for MTEC) with antibodies as indicated.

    Int J Cancer. 2019, 144(4):777-787. Nutlin-3a purchased from Selleck.

    Protein expression of p53, TAZ and CYP24A1 were detected by western blot after treatment with Nutlin 3a in CCLP-1.

    Cancer Lett, 2016, 381(2):370-9. Nutlin-3a purchased from Selleck.

  • Assessment of cell viability with WST1 tetrazolium salt assays in TP53 WT and KO isogenic cell lines after exposure to Nutlin-3a.

    Br J Haematol, 2017, 177(1):80-94. Nutlin-3a purchased from Selleck.

    C) Control-threated cells show an strong nuclear expression of MDM2 and predominantly cytoplasmic localization of FOXM1. D) After treatment with nutlin-3a, the MDM2 immunoreactivity shifted to the perinuclear space indicating a de novo 952 MDM2 synthesis as result of increased p53 activity. In those cells, FOXM1 expression is lost due to p53 activation.

    Neuroendocrinology, 2018, 107(1):1-23. Nutlin-3a purchased from Selleck.

  • Protein expression of TP53 and p21 of ovarian cancer cell lines after treated with Nutlin-3a for 24, 48 and 72 hours at their corresponding IC50 as indicated. C, untreated control; *, cancer cell lines carrying TP53 mutation. Het, heterozygous TP53 mutation; hom, homozygous TP53 mutation.

    PLoS One, 2015, 10(8):e0135101.. Nutlin-3a purchased from Selleck.

Purity & Quality Control

Choose Selective Mdm2 Inhibitors

Biological Activity

Description Nutlin-3a, the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay.
Features Highly selective MDM2 inhibitor with a much lower effect on MDMX. Most effective on tumors with wild type p53.
Targets
p53/MDM2 interaction [3]
(Cell-free assay)
90 nM
In vitro

Nutlin-3a displaces p53 from the binding pocket of MDM2 and thereby releases p53 from inhibition and proteasomal degradation, leading to induction of its downstream targets, cell cycle arrest, and apoptosis. Seven days of incubation with 10 μM nutlin-3a led to >90% inhibition of NIH3T3 cells’ growth[1]. Nutlin-3a stabilizes and activates p53, and induces p21 expression in a dose-dependent manner[1]. Nutlin-3a effectively depletes the S-phase compartment to 0.2-2% and increases the G1- and G2/M-phase compartments[1]. Nutlin-3a induces apoptosis in ~60% of SJSA-1 and MHM cells after 40 h, which increased further after 60 h (85% and 65%, respectively) [1].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 NUTab2R7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFf6SXlKSzVyPUCuOlEzOzdizszN M37zN3NCVkeHUh?=
H4 NXLLcVZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkmwTWM2OD1yLk[2Nlgh|ryP NELGRWZUSU6JRWK=
PA-1 NY[3eGtRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLQTWM2OD1yLki3NFk3KM7:TR?= NXSwNmNrW0GQR1XS
NKM-1 M2rxTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTFwMES5N|Eh|ryP MYDTRW5ITVJ?
NEC8 MlvoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHIUnJKSzVyPUGuNlE2PzJizszN MYjTRW5ITVJ?
EoL-1-cell MofnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3iTWM2OD1zLkK2O|AyKM7:TR?= NGPSV25USU6JRWK=
K5 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHpTWM2OD1zLkSyNFczKM7:TR?= MnXzV2FPT0WU
QIMR-WIL MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnriTWM2OD1zLk[wPFU1KM7:TR?= NGnhN5VUSU6JRWK=
MOLT-16 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVH0UYhwUUN3ME2xMlc5PjB2IN88US=> NXvISlBqW0GQR1XS
CHP-212 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fpOWlEPTB;MT64NVM3QSEQvF2= NELRZWNUSU6JRWK=
CTB-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\oVpJQUUN3ME2yMlAzOjR4IN88US=> NGjhXolUSU6JRWK=
MOLT-4 MmHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTJwM{K4OVMh|ryP MnH0V2FPT0WU
A101D MorPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVv1TWEzUUN3ME2yMlM2ODFizszN M4rvfXNCVkeHUh?=
DOHH-2 MoH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTJwNEKyO|kh|ryP NHnhfo5USU6JRWK=
ES4 NX7YV2V7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlixTWM2OD1{LkSzNVU2KM7:TR?= MY\TRW5ITVJ?
SW780 NEDuRYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjjUnB5UUN3ME2yMlUxQDh|IN88US=> NEDyNWNUSU6JRWK=
VA-ES-BJ NYT3d4FRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUToVGR2UUN3ME2yMlU1OTFizszN NIe3O21USU6JRWK=
RPMI-8866 MnHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTJwNU[yNVQh|ryP NI\wbY9USU6JRWK=
ML-2 NFvoN|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjGUlB7UUN3ME2yMlU3PTd4IN88US=> MXHTRW5ITVJ?
MSTO-211H MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfNXpJ5UUN3ME2yMlU4PDVzIN88US=> MofvV2FPT0WU
JVM-3 NV70cok{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTJwNUmzNlQh|ryP NVPYXVVmW0GQR1XS
A3-KAW MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jTeGlEPTB;Mj62NVgyQCEQvF2= MkHYV2FPT0WU
DK-MG NXTMS|ZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTJwNkK0O|Eh|ryP Mm\yV2FPT0WU
LNCaP-Clone-FGC MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojwTWM2OD1{Lk[0N|E5KM7:TR?= MkTGV2FPT0WU
HT-144 NWrae4N7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHi1RldKSzVyPUKuOlQ2PzdizszN M2DYUnNCVkeHUh?=
NB69 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzoNGUyUUN3ME2yMlY2OzN2IN88US=> NUPkUm5WW0GQR1XS
A172 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTTUHBKSzVyPUKuOlc2QDhizszN NVjDTVNkW0GQR1XS
RS4-11 M3Toc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTJwN{K0NFch|ryP MUDTRW5ITVJ?
DU-4475 MoG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlv0TWM2OD1{Lke5OVAzKM7:TR?= NEnVb5VUSU6JRWK=
SJSA-1 NHnnfYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTJwOEK1OVYh|ryP Mn;0V2FPT0WU
BV-173 NIDNR|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzu[4xEUUN3ME2yMlg1PDN7IN88US=> NH\xTXdUSU6JRWK=
U-2-OS NX;EWJd2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTQ[ZZKSzVyPUKuPVExPyEQvF2= MUHTRW5ITVJ?
CHP-134 NXXpbIRST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTJwOUO4PFIh|ryP MkjvV2FPT0WU
D-502MG MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XKcmlEPTB;Mj65O|E2PCEQvF2= Mn63V2FPT0WU
KS-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTNwMEG2NlMh|ryP M3XzbHNCVkeHUh?=
A204 M{DlcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHUTWM2OD1|LkC1OVg5KM7:TR?= NEDsc3BUSU6JRWK=
KGN NHTnO25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDUVnJKSzVyPUOuNFg1QTZizszN NXrzfIpSW0GQR1XS
NCI-H292 M{j5[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrFPHhKSzVyPUOuNVIxOjhizszN NEKwfVZUSU6JRWK=
CAKI-1 NFLxb2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4P2b2lEPTB;Mz6xNlY6PCEQvF2= M3[2U3NCVkeHUh?=
C2BBe1 Ml6xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LpS2lEPTB;Mz6xO|AzPiEQvF2= M37KOnNCVkeHUh?=
NB10 M3vkT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTrR4RNUUN3ME2zMlIxQTZ4IN88US=> M1T6d3NCVkeHUh?=
MHH-NB-11 M3qySGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\NTWM2OD1|LkK2PFI4KM7:TR?= NHjxcXlUSU6JRWK=
NCI-SNU-1 M2G1SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LXTmlEPTB;Mz6yO|g1OyEQvF2= NHfEXFhUSU6JRWK=
HCT-116 M2DRdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXOw[FRsUUN3ME2zMlMxOzN3IN88US=> MlewV2FPT0WU
G-401 NInvUmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{W3eGlEPTB;Mz6zOlMzOiEQvF2= NGnaO5pUSU6JRWK=
MN-60 Mn[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVja[YpUUUN3ME2zMlQ1ODl{IN88US=> M4P0UXNCVkeHUh?=
SW982 NGfSU4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NET0d2JKSzVyPUOuOVA5PDhizszN NFnHSIpUSU6JRWK=
RKO M2jnd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTNwNUO5N|Yh|ryP MUXTRW5ITVJ?
D-283MED MmLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTNwNUe5PFYh|ryP NF;ZPGFUSU6JRWK=
LB996-RCC Mn7xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHDTWM2OD1|Lk[yOVU5KM7:TR?= MlPOV2FPT0WU
A549 M4r0eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGf0NI9KSzVyPUOuOlM2PTJizszN MkjnV2FPT0WU
LB2241-RCC MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTNwNkW3NFgh|ryP MXnTRW5ITVJ?
SK-HEP-1 NIHmeWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;l[JJMUUN3ME2zMlc1Ojl5IN88US=> MWPTRW5ITVJ?
G-402 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{K0V2lEPTB;Mz64NFg{OiEQvF2= NH7EToxUSU6JRWK=
GOTO NWTiW5l{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPVOmVtUUN3ME2zMlg1OzN|IN88US=> NGL4PHBUSU6JRWK=
LOXIMVI MknXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvlTWM2OD1|Lki1Olc2KM7:TR?= NUTTfohpW0GQR1XS
NH-12 MojqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTRwMEG5OVkh|ryP M{PDc3NCVkeHUh?=
CTV-1 NXrKTo44T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\NTWM2OD12LkC3PVc{KM7:TR?= MWDTRW5ITVJ?
CP50-MEL-B MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPyTWM2OD12LkK0N|kzKM7:TR?= MVrTRW5ITVJ?
RH-18 MoHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTRwMke3NFYh|ryP NIfZd2ZUSU6JRWK=
NB17 NYC1cZZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmf2TWM2OD12LkOxO|Y5KM7:TR?= MkP0V2FPT0WU
A375 M3rOVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfnbpZKSzVyPUSuN|M2OjRizszN Mo\uV2FPT0WU
IST-MES1 Mle1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn2xTWM2OD12LkSxOFEyKM7:TR?= MknrV2FPT0WU
MZ2-MEL MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXT2T3ljUUN3ME20MlUxOTV3IN88US=> MmrxV2FPT0WU
CAL-54 MkTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M174UGlEPTB;ND61N|AyQSEQvF2= M4jTbHNCVkeHUh?=
NCI-H28 M{fxRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknQTWM2OD12Lk[yO|E4KM7:TR?= M4PnXHNCVkeHUh?=
D-247MG MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTRwN{WwO|Ih|ryP NUS1bmVlW0GQR1XS
NCI-H460 M3ftNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYi1[Ig3UUN3ME20MlkyOTJ5IN88US=> M4DZfXNCVkeHUh?=
MCF7 Mm[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jqXmlEPTB;NT60OFI1PCEQvF2= NXLsToxqW0GQR1XS
697 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\He25VUUN3ME21MlQ1PTVizszN NH3Ze5pUSU6JRWK=
ONS-76 NXLUenM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vIO2lEPTB;NT61O|AxQSEQvF2= M1nzRXNCVkeHUh?=
C32 MmniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTVwNkCwNlkh|ryP NX7s[45[W0GQR1XS
OS-RC-2 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7mTWM2OD13LkezPFg4KM7:TR?= MXLTRW5ITVJ?
MEL-HO M{P1NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUflWVQ6UUN3ME21Mlg2PjZ5IN88US=> NXfQV5hSW0GQR1XS
LoVo M33DXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjR[JdKSzVyPU[uNFE3OjRizszN NWHsVm9tW0GQR1XS
AGS NYHwTFNVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPxTWM2OD14LkG0PFI5KM7:TR?= MkHlV2FPT0WU
GI-ME-N NUT2PHhYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVu4cJlvUUN3ME22MlIzPDJzIN88US=> MojOV2FPT0WU
H-EMC-SS NXy4WXhjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2S1dGlEPTB;Nj6zPFYh|ryP NHztZmlUSU6JRWK=
RVH-421 MlPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTZwNEK0Nlgh|ryP MYXTRW5ITVJ?
SW954 M1i1b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzrbHhKSzVyPU[uOVU2PzJizszN MYrTRW5ITVJ?
NB5 MkDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7qTWM2OD14LkW2NVg{KM7:TR?= MoizV2FPT0WU
NCI-H2122 NXnROZpkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\RenZKUUN3ME22MlU5Pzl|IN88US=> NVTtUYk3W0GQR1XS
AM-38 MoLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjLOYlUUUN3ME22Mlc2PjN7IN88US=> NXTI[mpjW0GQR1XS
KNS-81-FD M1\l[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{WxemlEPTB;Nj63OlQ6PCEQvF2= M{fvenNCVkeHUh?=
LS-513 NX\VRVQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHJTWM2OD14Lke5NFI3KM7:TR?= M4TUWnNCVkeHUh?=
A427 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLITWM2OD14Lki3PFI6KM7:TR?= MW\TRW5ITVJ?
WM-115 Ml;MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTZwOUOyN{DPxE1? MVzTRW5ITVJ?
COLO-829 NG\3WZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXzdZdKSzVyPUeuNlQyQDhizszN Mkj1V2FPT0WU
NCI-H1650 MoDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TNemlEPTB;Nz6zPVIzQCEQvF2= NHKwUWhUSU6JRWK=
NCI-H358 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfrTWM2OD15LkS0PFc6KM7:TR?= NWjmdZd4W0GQR1XS
HT-1080 NYTNS4lDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jMOGlEPTB;Nz60PFI2PCEQvF2= MV3TRW5ITVJ?
HCC2218 M2DIVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPZZpB5UUN3ME23MlYzQTdizszN NYf5XGlxW0GQR1XS
NCI-H661 NEDxTGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXtXZFIUUN3ME23Mlg4ODZ7IN88US=> MYXTRW5ITVJ?
KM-H2 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfiSXRNUUN3ME23Mlg5Pjl2IN88US=> NFX0XXBUSU6JRWK=
RPMI-2650 M33DVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2e2N2lEPTB;Nz65OFQyPCEQvF2= MnPvV2FPT0WU
NCI-H226 NXTEN3RRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\xNmdIUUN3ME24MlIyOTJ{IN88US=> MXjTRW5ITVJ?
MKN45 NYLwTYQxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPoTWM2OD16LkK2OlAzKM7:TR?= NHPndZhUSU6JRWK=
D-392MG M{DJWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRThwNUK3NlIh|ryP M3\GOHNCVkeHUh?=
RCC10RGB MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzYTWM2OD16Lki2Olk2KM7:TR?= M2TYOHNCVkeHUh?=
CAL-51 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTlwMUCyOVEh|ryP M4e1eHNCVkeHUh?=
COLO-678 M1LEUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDUPG5KSzVyPUmuN|I5OTFizszN NHTjZmdUSU6JRWK=
SK-MEL-24 NUixN3FGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYD5eXE3UUN3ME25MlU2QDV4IN88US=> M3n6c3NCVkeHUh?=
SK-MEL-30 MlHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\qTWM2OD17Lkm0OFc3KM7:TR?= NYTZZXN5W0GQR1XS
MMAC-SF NEnMUYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjqT45KSzVyPUGwMlM6PjFizszN MknDV2FPT0WU
NTERA-S-cl-D1 MljsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTFyLk[1NFgh|ryP NYLWU3llW0GQR1XS
NB12 NIDhUXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTFzLkWwN{DPxE1? MUPTRW5ITVJ?
UACC-257 MlHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn[wTWM2OD1zMT64Olk2KM7:TR?= MWHTRW5ITVJ?
LAN-6 MoTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLtTWM2OD1zMT65PVI5KM7:TR?= NHXre|lUSU6JRWK=
SW1573 NFHlUlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLOOHNMUUN3ME2xNk4{ODh4IN88US=> NUHGd491W0GQR1XS
NMC-G1 Mn;vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3tbHF{UUN3ME2xNk41OTd3IN88US=> Ml;oV2FPT0WU
SHP-77 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTF{LkW1O|Qh|ryP NF74U5NUSU6JRWK=
IGROV-1 M4HwN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTF{Lk[1O|Mh|ryP NG\2dlJUSU6JRWK=
22RV1 NEDMVWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1myWGlEPTB;MUKuPFA2QSEQvF2= MXfTRW5ITVJ?
SK-MEL-3 M{G5UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzwdFdKSzVyPUGzMlM6PzNizszN MYjTRW5ITVJ?
NCI-H1563 MlXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIP4Vm5KSzVyPUGzMlQzODJizszN NV3jS4pZW0GQR1XS
IGR-1 NV7vXVN1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVywfIRjUUN3ME2xOE4xOzR5IN88US=> NUn0em1IW0GQR1XS
EW-3 M4jmSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{C2VWlEPTB;MUSuNVY{QSEQvF2= Ml\HV2FPT0WU
JEG-3 NH;vdohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLm[HhqUUN3ME2xOE41QTV|IN88US=> NID0VIpUSU6JRWK=
ES3 M{LyVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTF2Lk[1OlIh|ryP MoPBV2FPT0WU
MDA-MB-175-VII MlT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXL4S4tzUUN3ME2xOE44OTFzIN88US=> M36wd3NCVkeHUh?=
P30-OHK M2mzOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTITWM2OD1zNT6wOFk3KM7:TR?= MmHjV2FPT0WU
GP5d MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTF3LkG0OlYh|ryP M1rWW3NCVkeHUh?=
HMV-II NFHG[G9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjZZWhKSzVyPUG1MlM{OzNizszN M174OXNCVkeHUh?=
COLO-679 M2W1Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TWTWlEPTB;MUWuOVAyKM7:TR?= MkLoV2FPT0WU
JAR NWXvfpYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml2wTWM2OD1zNT63NlA2KM7:TR?= NGi1ZppUSU6JRWK=
NCI-H1666 MkTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTF3LkmzPVkh|ryP MVjTRW5ITVJ?
SW48 NHLNd3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTF3Lkm1NVYh|ryP NWPHXolFW0GQR1XS
NCI-H720 MnjNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo[4TWM2OD1zNT65PVg6KM7:TR?= Mn7MV2FPT0WU
HT-1197 M3O0cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmH1TWM2OD1zNj6wN|UzKM7:TR?= MnzqV2FPT0WU
HL-60 NUHj[Zh7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\odGlEPTB;MU[uNFM5PCEQvF2= NITBO21USU6JRWK=
BEN M1rpV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4T5T2lEPTB;MU[uOVY{QCEQvF2= MXzTRW5ITVJ?
HAL-01 NFTweXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzTUpJkUUN3ME2xOk45QTB7IN88US=> NEXONoxUSU6JRWK=
SW900 NGq2XVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrmZoVKSzVyPUG2MlkyOzJizszN NULmWZc3W0GQR1XS
SBC-1 NFr0UpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYW2emxrUUN3ME2xO{42PDJ7IN88US=> NI\SS5RUSU6JRWK=
SH-4 M1zCSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXe2O3hQUUN3ME2xO{42QDRzIN88US=> MV7TRW5ITVJ?
UACC-62 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHj6d|dKSzVyPUG3Mlc3OzdizszN NVjad3d3W0GQR1XS
BHT-101 NGTNWYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmD3TWM2OD1zOT64O|A2KM7:TR?= M1TJcHNCVkeHUh?=
DB MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rZPWlEPTB;MkGuOVY1QSEQvF2= NFfRZXhUSU6JRWK=
SK-MEL-1 NGfpblNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LpSWlEPTB;MkGuOVg4OiEQvF2= NI\jOlFUSU6JRWK=
NCI-H747 NH36dllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGf3PW9KSzVyPUKyMlc{PzlizszN MW\TRW5ITVJ?
SK-LU-1 MojSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXRcohGUUN3ME2yN{4{PTJ2IN88US=> M1P6fnNCVkeHUh?=
KG-1 M4XOd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrxTWM2OD1{Mz60PVQ3KM7:TR?= M2XTOHNCVkeHUh?=
LXF-289 NWjnOoxvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzYXnh1UUN3ME2yN{44OTRizszN M2DvNHNCVkeHUh?=
HCC1954 NWn4bYtnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfU[YduUUN3ME2yOE45QDR2IN88US=> NFm1OWRUSU6JRWK=
Ramos-2G6-4C10 M4nJRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDnNYhKSzVyPUK2MlQ6QDFizszN MlPPV2FPT0WU
DBTRG-05MG MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LlPWlEPTB;Mk[uOlQ5QCEQvF2= MWLTRW5ITVJ?
NCI-H2052 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;jTmlEPTB;MkeuOVY5PCEQvF2= NUfWdJlHW0GQR1XS
RMG-I NVXi[21iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTJ7LkSxN|kh|ryP MUPTRW5ITVJ?
H9 NG[2dJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7ac4xKSzVyPUOxMlMxODhizszN MlPZV2FPT0WU
GR-ST M1LyS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XPdWlEPTB;M{KuOFQ2OyEQvF2= MnjiV2FPT0WU
Mo-T MlHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTN{LkWwOFYh|ryP NILvNIlUSU6JRWK=
SW1088 M4nLTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoK1TWM2OD1|Mj65PFAyKM7:TR?= NUfmTpU{W0GQR1XS
LB2518-MEL Mn3hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWP2bmRnUUN3ME2zN{4xPzl5IN88US=> Mm\2V2FPT0WU
NCI-H82 NUH3[plNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjXXo15UUN3ME2zN{4yPjZzIN88US=> NF;JfFdUSU6JRWK=
LAMA-84 MmPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\BTWM2OD1|ND62NFc{KM7:TR?= Ml22V2FPT0WU
KYSE-450 M2Txe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXQTWM2OD1|ND62O|c3KM7:TR?= MVXTRW5ITVJ?
LU-99A MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HtR2lEPTB;M{WuNFAxPyEQvF2= MWPTRW5ITVJ?
BE-13 M{DjbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoWyTWM2OD1|NT62OVQ2KM7:TR?= Mm\lV2FPT0WU
GAK MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1e3N2lEPTB;M{WuOlk2KM7:TR?= M1PKbHNCVkeHUh?=
NCI-H1573 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLOTWM2OD1|NT64PFE5KM7:TR?= Mo[4V2FPT0WU
AsPC-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTN4LkG1Nlch|ryP MnXJV2FPT0WU
HDLM-2 M1T0XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPHZmdZUUN3ME2zOk4{OTZizszN MWnTRW5ITVJ?
NCI-H441 NEfTbJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTN5LkC2PVEh|ryP M1G3[XNCVkeHUh?=
CAL-27 NEi1V2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3XdGFKSzVyPUO3MlczOzFizszN NVL5UFd1W0GQR1XS
OVCAR-3 NHG2RlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoP3TWM2OD1|OT6zNVgyKM7:TR?= Ml;6V2FPT0WU
RPMI-8226 NVKz[HYyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVm5UllJUUN3ME2zPU42QThizszN M3rRT3NCVkeHUh?=
EFO-21 M2fhfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHqTWM2OD12MD61PFE1KM7:TR?= MWDTRW5ITVJ?
SNU-C2B M4fwOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\xN4VbUUN3ME20NU42ODh2IN88US=> MmC3V2FPT0WU
VM-CUB-1 MofIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYC4V3B1UUN3ME20N{45ODN5IN88US=> MojqV2FPT0WU
NCI-H2087 M1;UWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;UOotEUUN3ME20OU4xOjN|IN88US=> MoXuV2FPT0WU
EW-16 MlLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTR4LkOxN|ch|ryP MkfwV2FPT0WU
SK-N-AS M2XTS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn[1TWM2OD12Nj63NVY4KM7:TR?= NEDrT4VUSU6JRWK=
COR-L105 NVnGeWx5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7wTWM2OD12Nj64PFU4KM7:TR?= NF7hWHVUSU6JRWK=
DEL NWC3SVQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLaTWM2OD12OD6wOFI6KM7:TR?= Mly3V2FPT0WU
JVM-2 NHX5OItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;afndmUUN3ME20PE4xPTV6IN88US=> M32yUnNCVkeHUh?=
KARPAS-45 NWqx[WhET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLWTWM2OD12OT60OVM5KM7:TR?= MmPtV2FPT0WU

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p53 / MDM2 / p21 / Bax / Bak / Noxa / cleaved caspase / pro-caspase; 

PubMed: 16014563     


Expression of apoptosis- and cell-cycle–associated proteins in OCI-AML-3 cells, which were treated with 5 μM Nutlin-3a for the indicated times. Nutlin-3a induced increased protein expression of p53, MDM2, and p21 in OCI-AML-3 cells in a time-dependent fashion. Nutlin-3a induced Noxa, a BH3-only member of the Bcl-2 family, followed by caspase activation. β-actin was used to confirm equal loading of proteins. Arrowheads indicate cleared caspases.

BMI-1; 

PubMed: 26887044     


Western blot analysis of BMI-1 and actin was performed in BV-173, SUP-B15, NALM-6, NALM-19 and REH cell lines after 24 hours treatment with increasing concentrations of Nutlin-3a (1 μM, 2 μM, 5 μM) and with DMSO control. 

p53-Ser15 / p53-Ser37 / p53-Lys382 / MDM2 / CDC2 / PLK1 / HSC70; 

PubMed: 23666059     


Expression of the indicated proteins in whole-cell lysates of cells treated for 96 h with 50 μM resveratrol (R), 5 μM nutlin-3a (N), or co-treated with both substances (RN).

16014563 26887044 23666059
Immunofluorescence
p-p21 / β-actin; 

PubMed: 31083332     


Cells were treated with fluoride (5 mM) with/without Nutlin-3a for 24 h. p-p21 (green), nucleus (DAPI; blue) and β-actin (red) expression were detected by immunocytochemistry. Nutlin-3a addition augmented p-p21 expression compared to NaF treatment alone.

P53; 

PubMed: 21394100     


At 12 h following treatment with nutlin-3a, DoHH2 and MCA cells had increased levels of p53 visualized by immunofluorescence. p53 localization was predominantly nuclear. The 4',6-diamidino-2-phenylindole was used as counterstain of the nuclei.

Ac-p300; 

PubMed: 30240745     


HepG2 cells were treated with 5 μM Nutlin-3a for 24 hr, and the levels of Ac-p300 and p53 were assessed by co-immunofluorescence. Fluorescence intensity of Ac-p300 in control cells versus Nutlin-3a-treated cells have been quantified (represented as mean ± SD, unpaired two-tailed Student's t test, n = 50 of three independent experiments). Scale bar, 10 μm.

31083332 21394100 30240745
Growth inhibition assay
Cell viability; 

PubMed: 26248031     


All 15 cell lines were plated in 96-well plates. After 24h, media was exchanged and cells were treated with incremental concentrations of Nutlin-3a (1 μM, 5 μM, 10 μM, 25 μM, 50 μM, and 70 μM). After 72h of Nutlin-3a treatment, cell viability was measured by WST assay and compared to untreated control.

26248031
In vivo Nutlin-3a suppresses xenograft growth in a dose-dependent fashion with the highest dose (200 mg/kg) showing a substantial tumor shrinkage [1]. Nutlin-3 is a selective activator of the p53 pathway in vivo and highly efficacious against SJSA-1 osteosarcoma tumors[1]. Tumors with wild-type p53 and mdm2 gene amplification will respond best to therapy with Nutlin-3a.

Protocol

Kinase Assay:[3]
+ Expand

Biacore studies:

Competition assays are performed on a Biacore S51. A Series S Sensor chip CM5 is derivatized for immobilization of a PentaHis antibody for capture of the His-tagged p53. The level of capture is ~ 200 response units (1 response unit corresponds to 1 pg of protein per mm 2). The concentration of MDM2 protein is kept constant at 300 nM. Test compounds are dissolved in DMSO at 10 mM and further diluted to make a concentration series of inhibitor in each MDM2 test sample. The assays are run at 25 °C in running buffer (10 mM Hepes, 0.15 M NaCl, 2% DMSO). MDM2-p53 binding in the presence of inhibitor is calculated as a percentage of binding in the absence of inhibitor and IC50 is calculated using Microsoft Excel
Cell Research:[2]
+ Expand
  • Cell lines: OSA, T778, RMS13, U2OS, SaOS-2
  • Concentrations: ~5 μM
  • Incubation Time: 120 h
  • Method: SRB
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: SJSA-1 xenograft
  • Formulation: 1% Klucel, 0.1% Tween 80
  • Dosages: 50, 100, 200 mg/kg twice daily
  • Administration: oral
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (171.97 mM)
Ethanol 100 mg/mL (171.97 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+55% PEG 300+ddH2O
For best results, use promptly after mixing.
8mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 581.49
Formula

C30H30Cl2N4O4

CAS No. 675576-98-4
Storage powder
in solvent
Synonyms (-)-Nutlin-3

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is the difference between S1061 (Nutlin-3) and S8059 (Nutlin-3a)?

  • Answer:

    S1061 is a racemic mixture of Nutlin3a and Nutlin3b. s8059 is the active enantiomer of Nutlin3.

Mdm2 Signaling Pathway Map

Related Mdm2 Products

Tags: buy Nutlin-3a | Nutlin-3a supplier | purchase Nutlin-3a | Nutlin-3a cost | Nutlin-3a manufacturer | order Nutlin-3a | Nutlin-3a distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID